Tazeen Ahmad
Stock Analyst at B of A Securities
(3.41)
# 1,004
Out of 5,022 analysts
214
Total ratings
48.41%
Success rate
3.83%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $31.90 | +66.14% | 1 | Oct 9, 2025 | |
| PHVS Pharvaris | Upgrades: Neutral | $16 → $27 | $20.96 | +28.82% | 4 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $469.36 | +10.79% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $85.96 | +20.99% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $208.71 | +10.20% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $812.95 | +9.11% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $21.43 | -25.34% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $66.11 | +14.96% | 19 | Aug 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $27 | $20.36 | +32.61% | 16 | Aug 7, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $102.61 | +30.59% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $24 | $23.15 | +3.67% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.16 | +55.19% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $105.20 | -9.70% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.42 | +133.64% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $10.12 | -60.47% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.80 | - | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $15.21 | +77.51% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $9.41 | +197.56% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $94.83 | -26.18% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.97 | +301.20% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $137.23 | +30.44% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.54 | +90.64% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $4.58 | -34.50% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.04 | +86.57% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $8.69 | -76.99% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $31.69 | +139.82% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.00 | +233.33% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.50 | +300.00% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $11.23 | +33.57% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.11 | -51.34% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.30 | +361.54% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $13.64 | +9.97% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $52.52 | +14.24% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $3.23 | +395.36% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $14.79 | +190.74% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $202.06 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $15.65 | +1,816.93% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.36 | +281.36% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $22.73 | +111.17% | 6 | Oct 10, 2018 |
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $31.90
Upside: +66.14%
Pharvaris
Oct 9, 2025
Upgrades: Neutral
Price Target: $16 → $27
Current: $20.96
Upside: +28.82%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $469.36
Upside: +10.79%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $85.96
Upside: +20.99%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $208.71
Upside: +10.20%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $812.95
Upside: +9.11%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $21.43
Upside: -25.34%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $66.11
Upside: +14.96%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $20.36
Upside: +32.61%
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $102.61
Upside: +30.59%
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $23.15
Upside: +3.67%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $5.16
Upside: +55.19%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $105.20
Upside: -9.70%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $6.42
Upside: +133.64%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $10.12
Upside: -60.47%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.80
Upside: -
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $15.21
Upside: +77.51%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $9.41
Upside: +197.56%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $94.83
Upside: -26.18%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.97
Upside: +301.20%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $137.23
Upside: +30.44%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $11.54
Upside: +90.64%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $4.58
Upside: -34.50%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.04
Upside: +86.57%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $8.69
Upside: -76.99%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $31.69
Upside: +139.82%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.00
Upside: +233.33%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.50
Upside: +300.00%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $11.23
Upside: +33.57%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.11
Upside: -51.34%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.30
Upside: +361.54%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $13.64
Upside: +9.97%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $52.52
Upside: +14.24%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $3.23
Upside: +395.36%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $14.79
Upside: +190.74%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $202.06
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $15.65
Upside: +1,816.93%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.36
Upside: +281.36%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $22.73
Upside: +111.17%